Tenet Healthcare Corporation (THC)
| Market Cap | 21.77B +25.5% |
| Revenue (ttm) | 21.81B +5.4% |
| Net Income | 2.24B +51.0% |
| EPS | 25.75 +64.5% |
| Shares Out | 80.52M |
| PE Ratio | 10.60 |
| Forward PE | 13.09 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 154,602 |
| Open | 276.96 |
| Previous Close | 275.13 |
| Day's Range | 270.02 - 278.39 |
| 52-Week Range | 157.58 - 283.05 |
| Beta | 1.20 |
| Analysts | Buy |
| Price Target | 285.32 (+5.55%) |
| Earnings Date | Oct 29, 2026 |
About THC
Tenet Healthcare Corporation operates as a diversified healthcare services company in the United States. The company operates through two segments: Hospital Operations and Services, and Ambulatory Care. Its general hospitals offer acute care services, operating and recovery rooms, radiology and respiratory therapy services, clinical laboratories, and pharmacies. The company also provides intensive and critical care, and/or coronary care units; cardiovascular, digestive disease, neurosciences, musculoskeletal, and obstetrics services; outpatient... [Read more]
Financial Performance
In 2025, Tenet Healthcare's revenue was $21.31 billion, an increase of 3.07% compared to the previous year's $20.68 billion. Earnings were $1.41 billion, a decrease of -56.03%.
Financial StatementsAnalyst Summary
According to 23 analysts, the average rating for THC stock is "Buy." The 12-month stock price target is $285.32, which is an increase of 5.55% from the latest price.
News
Tenet Healthcare price target raised to $307 from $283 at Guggenheim
Guggenheim raised the firm’s price target on Tenet Healthcare (THC) to $307 from $283 and keeps a Buy rating on the shares. The firm anticipates Tenet will “stick to its…
Tenet to Report Its Third Quarter 2026 Results on October 29
DALLAS--(BUSINESS WIRE)--Tenet Healthcare Corporation (NYSE: THC) will release its third quarter 2026 results before the market opens on Thursday, October 29, 2026, to be followed by a conference call...
BMO starts Tenet at Market Perform, says execution reflected in valuation
BMO Capital initiated coverage of Tenet Healthcare (THC) with a Market Perform rating and $265 price target Tenet’s expanding Ambulatory business increasingly leverages it to an end-market with more f...
Tenet Healthcare initiated with a Market Perform at BMO Capital
BMO Capital initiated coverage of Tenet Healthcare (THC) with a Market Perform rating and $265 price target
Tenet Healthcare Transcript: Wells Fargo 21st Annual Healthcare Conference
Expansion in high acuity ambulatory and hospital services is driving revenue and margin growth, supported by disciplined cost management, strategic investments, and favorable policy trends. Conifer's transformation and targeted AI investments are expected to further enhance efficiency and competitiveness.
Tenet Announces Upsizing and Pricing of Its $2.0 Billion Private Offering of Senior Notes
DALLAS--(BUSINESS WIRE)--Tenet Healthcare Corporation (NYSE: THC) today announced the pricing of the previously announced private placement offering and has agreed to issue and sell $2.0 billion in ag...
Tenet Announces Private Offering of Senior Notes to Refinance $1.5 Billion in Outstanding Notes
DALLAS--(BUSINESS WIRE)--Tenet Healthcare Corporation (NYSE: THC) today announced a private placement offering of $1.5 billion in aggregate principal amount of new senior notes due 2034 (the “notes”) ...
Tenet to Participate in the Wells Fargo Healthcare Conference
DALLAS--(BUSINESS WIRE)--Tenet Healthcare Corporation (NYSE: THC) is scheduled to present at the Wells Fargo Healthcare Conference on Wednesday, September 9, 2026, beginning at 12:45 p.m. Eastern Time...
Tenet Healthcare price target raised to $285 from $275 at Raymond James
Raymond James raised the firm’s price target on Tenet Healthcare (THC) to $285 from $275 and keeps an Outperform rating on the shares. The company’s differentiated ASC exposure, manageable Medicaid…
Tenet Healthcare price target raised to $295 from $290 at BofA
BofA raised the firm’s price target on Tenet Healthcare (THC) to $295 from $290 and keeps a Buy rating on the shares. July data points better than Q2 for foot…
Tenet Healthcare price target raised to $290 from $250 at Mizuho
Mizuho raised the firm’s price target on Tenet Healthcare (THC) to $290 from $250 and keeps an Outperform rating on the shares. The firm cites stronger underlying performance for the…
Tenet Healthcare price target raised to $281 from $231 at Wells Fargo
Wells Fargo analyst Stephen Baxter raised the firm’s price target on Tenet Healthcare (THC) to $281 from $231 and keeps an Overweight rating on the shares. The firm cites higher…
Tenet Healthcare price target raised to $305 from $252 at Goldman Sachs
Goldman Sachs analyst Scott Fidel raised the firm’s price target on Tenet Healthcare (THC) to $305 from $252 and keeps a Buy rating on the shares. Shares have decisively outperformed…
Tenet Healthcare price target raised to $290 from $270 at Truist
Truist analyst David MacDonald raised the firm’s price target on Tenet Healthcare (THC) to $290 from $270 and keeps a Buy rating on the shares. The firm has updated its…
Tenet Healthcare price target raised to $274 from $254 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Tenet Healthcare (THC) to $274 from $254 and keeps an Overweight rating on the shares. Tenet’s “superior” operational execution is not yet…
Tenet Healthcare price target raised to $283 from $242 at Guggenheim
Guggenheim raised the firm’s price target on Tenet Healthcare (THC) to $283 from $242 and keeps a Buy rating on the shares. The firm remains positive on Tenet Healthcare, highlighting…
Tenet Healthcare price target raised to $280 from $210 at Baird
Baird analyst Michael Ha raised the firm’s price target on Tenet Healthcare (THC) to $280 from $210 and keeps a Neutral rating on the shares.
Tenet Healthcare price target raised to $285 from $250 at Stephens
Stephens raised the firm’s price target on Tenet Healthcare (THC) to $285 from $250 and keeps an Overweight rating on the shares. The firm attributes the company’s beat and higher…
Tenet Healthcare price target raised to $308 from $288 at UBS
UBS analyst AJ Rice raised the firm’s price target on Tenet Healthcare (THC) to $308 from $288 and keeps a Buy rating on the shares.
Tenet Healthcare price target raised to $274 from $254 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Tenet Healthcare (THC) to $274 from $254 and keeps an Overweight rating on the shares following what the firm calls ” another…
Tenet Healthcare price target raised to $263 from $233 at TD Cowen
TD Cowen analyst Ryan Langston raised the firm’s price target on Tenet Healthcare (THC) to $263 from $233 and keeps a Buy rating on the shares. The firm updated its…
Tenet Healthcare price target raised to $283 from $236 at RBC Capital
RBC Capital raised the firm’s price target on Tenet Healthcare (THC) to $283 from $236 and keeps an Outperform rating on the shares. The company’s Q2 results drove shares up…
Tenet Healthcare Earnings Call Transcript: Q2 2026
Q2 2026 saw strong revenue and margin growth, with adjusted EBITDA up 16.3% year-over-year and EPS up 52%. Guidance for 2026 was raised across revenue, EBITDA, and free cash flow, supported by high-acuity strategies, disciplined expense management, and robust capital deployment.
Tenet Healthcare Earnings release: Q2 2026
Tenet Healthcare released its Q2 2026 earnings on July 24, 2026, summarizing the period's financial results.
Tenet Healthcare Slides: Q2 2026
Tenet Healthcare has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 24, 2026.